Skip to main content

Table 5 Changes in medication use between 2016 and 2017 by medication subgroups among those who survived until Jan 1, 2018 (n = 8025)

From: Impact of co-payment level increase of antidiabetic medications on glycaemic control: an interrupted time-series study among Finnish patients with type 2 diabetes

 

Used only metformin in 2017

Used metformin and other OAD in 2017

Used only other diabetes medications than insulin or metformin in 2017

Used insulin and OAD (incl. metformin) in 2017

Used only insulin in 2017

Did not use antidiabetic medications in 2017

Used only metformin in 2016 (n = 2271)

1967 (89.0)

147 (6.7)

10 (0.5)

16 (0.7)

1 (0.1)

68 (3.1)

Used metformin and other OAD in 2016 (n = 1430)

42 (3.0)

1164 (83.5)

76 (5.5)

101 (7.3)

3 (0.2)

8 (0.6)

Used only other diabetes medications than insulin or metformin in 2016 (n = 726)

2 (0.3)

46 (6.8)

563 (83.7)

40 (5.9)

0

22 (3.3)

Used insulin and OAD (incl. metformin) in 2016 (n = 2112)

11 (0.6)

23 (1.1)

17 (0.9)

1889 (94.0)

63 (3.1)

7 (0.4)

Used only insulin in 2016 (n = 577)

0

0

1 (0.2)

35 (6.9)

461 (90.9)

10 (2.0)

  1. Abbreviations: OAD oral antidiabetic drug